Amit Noheria1, Peter Shrader2, Jonathan P Piccini2, Gregg C Fonarow3, Peter R Kowey4, Kenneth W Mahaffey5, Gerald Naccarelli6, Peter A Noseworthy7, James A Reiffel8, Benjamin A Steinberg2, Laine E Thomas2, Eric D Peterson2, Bernard J Gersh9. 1. Cardiovascular Division, Washington University, St. Louis, Missouri, USA. 2. Duke Clinical Research Unit, Durham, North Carolina, USA. 3. Department of Medicine, University of California Los Angeles, Los Angeles, California, USA. 4. Lankenau Medical Center and Jefferson Medical College, Wynnewood, Pennsylvania, USA. 5. Stanford Center for Clinical Research, Department of Medicine, Stanford University, Palo Alto, California, USA. 6. Penn State Heart and Vascular Institute, Hershey, Pennsylvania, USA. 7. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. 8. Division of Cardiology, Columbia University, New York, New York, USA. 9. Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: Gersh.Bernard@mayo.edu.
Abstract
OBJECTIVES: The study sought to evaluate clinical outcomes in clinical practice with rhythm control versus rate control strategy for management of atrial fibrillation (AF). BACKGROUND: Randomized trials have not demonstrated significant differences in stroke, heart failure, or mortality between rhythm and rate control strategies. The comparative outcomes in contemporary clinical practice are not well described. METHODS: Patients managed with a rhythm control strategy targeting maintenance of sinus rhythm were retrospectively compared with a strategy of rate control alone in a AF registry across various U.S. practice settings. Unadjusted and adjusted (inverse-propensity weighted) outcomes were estimated. RESULTS: The overall study population (N = 6,988) had a median of 74 (65 to 81) years of age, 56% were males, 77% had first detected or paroxysmal AF, and 68% had CHADS2 score ≥2. In unadjusted analyses, rhythm control was associated with lower all-cause death, cardiovascular death, first stroke/non-central nervous system systemic embolization/transient ischemic attack, or first major bleeding event (all p < 0.05); no difference in new onset heart failure (p = 0.28); and more frequent cardiovascular hospitalizations (p = 0.0006). There was no difference in the incidence of pacemaker, defibrillator, or cardiac resynchronization device implantations (p = 0.99). In adjusted analyses, there were no statistical differences in clinical outcomes between rhythm control and rate control treated patients (all p > 0.05); however, rhythm control was associated with more cardiovascular hospitalizations (hazard ratio: 1.24; 95% confidence interval: 1.10 to 1.39; p = 0.0003). CONCLUSIONS: Among patients with AF, rhythm control was not superior to rate control strategy for outcomes of stroke, heart failure, or mortality, but was associated with more cardiovascular hospitalizations.
OBJECTIVES: The study sought to evaluate clinical outcomes in clinical practice with rhythm control versus rate control strategy for management of atrial fibrillation (AF). BACKGROUND: Randomized trials have not demonstrated significant differences in stroke, heart failure, or mortality between rhythm and rate control strategies. The comparative outcomes in contemporary clinical practice are not well described. METHODS:Patients managed with a rhythm control strategy targeting maintenance of sinus rhythm were retrospectively compared with a strategy of rate control alone in a AF registry across various U.S. practice settings. Unadjusted and adjusted (inverse-propensity weighted) outcomes were estimated. RESULTS: The overall study population (N = 6,988) had a median of 74 (65 to 81) years of age, 56% were males, 77% had first detected or paroxysmal AF, and 68% had CHADS2 score ≥2. In unadjusted analyses, rhythm control was associated with lower all-cause death, cardiovascular death, first stroke/non-central nervous system systemic embolization/transient ischemic attack, or first major bleeding event (all p < 0.05); no difference in new onset heart failure (p = 0.28); and more frequent cardiovascular hospitalizations (p = 0.0006). There was no difference in the incidence of pacemaker, defibrillator, or cardiac resynchronization device implantations (p = 0.99). In adjusted analyses, there were no statistical differences in clinical outcomes between rhythm control and rate control treated patients (all p > 0.05); however, rhythm control was associated with more cardiovascular hospitalizations (hazard ratio: 1.24; 95% confidence interval: 1.10 to 1.39; p = 0.0003). CONCLUSIONS: Among patients with AF, rhythm control was not superior to rate control strategy for outcomes of stroke, heart failure, or mortality, but was associated with more cardiovascular hospitalizations.
Authors: Arun Govindapillai; Jafna L Cox; Lehana Thabane; Steve Doucette; Feng Xie; James H MacKillop; Antonio Ciaccia; Shurjeel H Choudhri; Joanna M Nemis-White; Laura M Hamilton; Ratika Parkash Journal: CJC Open Date: 2022-03-08
Authors: Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara Journal: Intern Emerg Med Date: 2021-12-02 Impact factor: 5.472
Authors: J'Neka S Claxton; Alanna M Chamberlain; Pamela L Lutsey; Lin Y Chen; Richard F MacLehose; Lindsay G S Bengtson; Alvaro Alonso Journal: Am J Med Date: 2020-04-19 Impact factor: 4.965
Authors: Vinita Subramanya; J'Neka S Claxton; Pamela L Lutsey; Richard F MacLehose; Lin Y Chen; Alanna M Chamberlain; Faye L Norby; Alvaro Alonso Journal: BMC Cardiovasc Disord Date: 2021-12-16 Impact factor: 2.298
Authors: Giuseppe Boriani; Gregory Y H Lip; Marco Proietti; Marco Vitolo; Stephanie L Harrison; Deirdre A Lane; Laurent Fauchier; Francisco Marin; Michael Nabauer; Tatjana S Potpara; Gheorghe-Andrei Dan Journal: Clin Res Cardiol Date: 2021-08-27 Impact factor: 5.460
Authors: Rachel S Kim; Steven Simon; Brett Powers; Amneet Sandhu; Jose Sanchez; Ryan T Borne; Alexis Tumolo; Matthew Zipse; J Jason West; Ryan Aleong; Wendy Tzou; Michael A Rosenberg Journal: JMIR Med Inform Date: 2021-12-06
Authors: Andreas Metzner; Anna Suling; Axel Brandes; Günter Breithardt; A John Camm; Harry J G M Crijns; Lars Eckardt; Arif Elvan; Andreas Goette; Laurent M Haegeli; Hein Heidbuchel; Josef Kautzner; Karl-Heinz Kuck; Luis Mont; G Andre Ng; Lukasz Szumowski; Sakis Themistoclakis; Isabelle C van Gelder; Panos Vardas; Karl Wegscheider; Stephan Willems; Paulus Kirchhof Journal: Europace Date: 2022-04-05 Impact factor: 5.214